FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sci Pharmtech's Free Cash Flow for the
three
months ended in Dec. 2025 was NT$-35 Mil. Sci Pharmtech's Revenue for the
three
months ended in Dec. 2025 was NT$355 Mil. Therefore, Sci Pharmtech's FCF Margin % for the quarter that ended in Dec. 2025 was -9.90%.
The historical rank and industry rank for Sci Pharmtech's FCF Margin % or its related term are showing as below:
TPE:4119'
s FCF Margin % Range Over the Past 10 Years
Min: -96.81 Med: 2.34 Max: 28.03
Current: -29.02
During the past 13 years, the highest FCF Margin % of Sci Pharmtech was 28.03%. The lowest was -96.81%. And the median was 2.34%.
TPE:4119's FCF Margin % is ranked worse than 85.07% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs TPE:4119: -29.02
Sci Pharmtech FCF Margin % Related Terms
Sci Pharmtech FCF Margin % Historical Data
* Premium members only.
The historical data trend for Sci Pharmtech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sci Pharmtech (TPE:4119) has a FCF Margin % of -9.90% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sci Pharmtech and its competitors. According to the industry distribution chart, Sci Pharmtech ranks #815 out of 958 companies in the Drug Manufacturers industry, placing it in the top 85.1%.
Is Sci Pharmtech's FCF Margin % too high?
Sci Pharmtech's current FCF Margin % is -9.90%. Based on the distribution chart, Sci Pharmtech ranks #815 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sci Pharmtech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #815 out of 958 companies for FCF Margin %. This places Sci Pharmtech in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sci Pharmtech and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current FCF Margin % is -9.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$96.43, compared to a current price of NT$44.50 — trading 53.9% below its estimated fair value. The current FCF Margin % is -9.90%. Sci Pharmtech's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current FCF Margin % is -9.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$44.50 is trading 53.9% below its estimated GF Value™ of NT$96.43.
GuruFocus considers Sci Pharmtech to be Possible Value Trap.
Key valuation signals for TPE:4119:
FCF Margin %: -9.90%
GF Value™: NT$96.43 vs. price of NT$44.50 (53.9% below fair value)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
67GF Score
Get the complete analysis for TPE:4119
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
